1-7 of 7
Paola Aimone
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Clinical Trials & Observations
Delphine Réa, Michael J. Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F. Apperley, Andre Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Koji Sasaki, Lynette Chee, Valentin García-Gutiérrez, Jorge E. Cortes, Paola Aimone, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Andreas Hochhaus
Journal: Blood
Blood (2021) 138 (21): 2031–2041.
https://doi.org/10.1182/blood.2020009984
Published: 2021
Includes: Supplemental data
Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Andreas Hochhaus, MD, Carla Boquimpani, MD, Delphine Rea, MDPhD, Yosuke Minami, MDPhD, Elza Lomaia, MD PhD, Sergey Voloshin, MD PhD, Anna G. Turkina, Prof., MD, Dong-Wook Kim, MD, Jane Apperley, FRCP, FRCPath, MB, Jorge E. Cortes, MD, Andre Abdo, MD, Laura Maria Fogliatto, MD PhD, Dennis Dong Hwan Kim, MD PhD, Philipp D le Coutre, MD, Susanne Saussele, MD, Mario Annunziata, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Naeem A. Chaudhri, MD, Lynette C.Y. Chee, MBBS,PhDFRACP,FRCPA, Valentín García Gutiérrez, MD PhD, Koji Sasaki, MD, Paola Aimone, MD, Alex Allepuz, MD MPH, Sarah Quenet, Véronique Bédoucha, Michael J. Mauro, MD
Journal: Blood
Blood (2020) 136 (Supplement_2): LBA-4.
https://doi.org/10.1182/blood-2020-143816
Published: 2020
Journal Articles

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Jose Valentín García Gutiérrez, MD PhD, Jerald P. Radich, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD PhD, Tamas Masszi, MD PhD Prof., Andrzej Hellmann, MD PhD, Jesper Stentoft, MD PhD, María Teresa Gomez Casares, MD PhD, Eibhlin Conneally, MB, PhD MRCP, MRCPath, Philipp D le Coutre, MD, Norbert Gattermann, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MD FRCPI, FRCPath, Paola Aimone, MD, Sai Li, MD PhD, Ksenia Titorenko, MS, David M. Ross, MD MBBS, PhD FRACP, FRCPA
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-137388
Published: 2020
Journal Articles

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Jorge E. Cortes, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Michael J. Mauro, MD, Andreas Hochhaus, MD, Delphine Rea, MDPhD, Yeow Tee Goh, MBBS, Jeroen Janssen, Juan Luis Steegmann, Michael C. Heinrich, MD, Moshe Talpaz, MD, Gabriel Etienne, MD PhD, Massimo Breccia, MD, Michael W. Deininger, MD PhD, Philipp D le Coutre, MD, Fabian Lang, MD, Paola Aimone, MD, Fotis Polydoros, Silvia Cacciatore, Laura Stenson, Dong-Wook Kim, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–50.
https://doi.org/10.1182/blood-2020-139677
Published: 2020
Journal Articles

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Clinical Trials & Observations
Nobuko Hijiya, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco Bautista, Stéphane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frédéric Millot, Paola Aimone, Alex Allepuz, Sara Quenet, Florence Hourcade-Potelleret, Sabine Hertle, Darintr Sosothikul
Journal: Blood
Blood (2019) 134 (23): 2036–2045.
https://doi.org/10.1182/blood.2019000069
Published: 2019
Includes: Supplemental data
Journal Articles

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Giuseppe Saglio, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, Surapol Issaragrisil, MD, Philipp Le Coutre, MD, Gabriel Etienne, MD PhD, Carla Boquimpani, MD, Richard E. Clark, MA, MD MRCP, FRCPath, Viviane Dubruille, MD, Ian W. Flinn, MD PhD, Slawomira Kyrcz-Krzemien, MD PhD, Ewa Medras, MD, Maria Zanichelli, MD, Israel Bendit, MD PhD, Manu Sondhi, MD PhD, Ksenia Titorenko, MS, Claire Nourry-Boulot, PhD, Paola Aimone, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2924.
https://doi.org/10.1182/blood-2019-128761
Published: 2019
Journal Articles

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

Delphine Rea, MD, Fabian Lang, MD, Dong-Wook Kim, MD PhD, Jorge E. Cortes, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Hironobu Minami, MD PhD, Massimo Breccia, MD, Daniel J. Deangelo, MD, Andreas Hochhaus, MD, Moshe Talpaz, MD, Yeow Tee Goh, MBBS,MD, Philipp le Coutre, MD, Michael W. Deininger, MD PhD, Gabriel Etienne, MD PhD, Manu Sondhi, MD PhD, Kaushal Mishra, PhD, Paola Aimone, MD, Janet Ng-Sikorski, PhD, Michael J. Mauro, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 792.
https://doi.org/10.1182/blood-2018-99-113609
Published: 2018